Assertio Therapeutics (ASRT) Misses Q3 EPS by 10c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. SPY
8. RCKT
9. CRWV
10. NVDA

Go back to Assertio Therapeutics (ASRT) Misses Q3 EPS by 10c, Revenues Beat

Assertio Reports Third Quarter 2020 Financial Results

November 6, 2020 6:00 AM EST

Reported Net Product Sales of $34.3 Million

Non-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020

Non-GAAP Net Product Sales Consistent with Pro-Forma Prior Year Quarter Despite COVID-19 Related Sales Disruptions and Effects of Sales Force Integration

Provides Updated Outlook for Remainder of 2020

LAKE FOREST, Ill., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a commercial-stage pharmaceutical... More